Biocon signs commercialization agreement with Juno Pharmaceuticals in Canada
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Dr. Singh proposes upskilling medicos with AI, Quantum and other newer technologies to meet the changing requirements of patient care
Lokavant provides clinical trial intelligence
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
The Main campaign started from October 2
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Subscribe To Our Newsletter & Stay Updated